Hyaluronidase cGMP >400 U/mg Source : Ovine testes

Added to your cart

Hyaluronidase cGMP >400 U/mg Source : Ovine testes

Cart subtotal: £0.00

View cart (0) Checkout

#SKU 081239H03

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team

Product Details

Testicular hyaluronidase is a typical glucosidase having both endohexosaminidase and transglycosidase activity. Substrates are hyaluronic acid and also chondroitin sulphate A andC. Products of hydrolysis are a series of oligosaccharides, mainly tetrasaccharides. Hyaluronidase is often used in conjunction with collagenase to dissociate the extracellular matrix between cells of animal tissue, in order to release viable cells for use in tissue culture. It may also be used to clarify synovial fluids in order to make cell counts possible.

081239H03

More information

Attributes

Description

  • Shipping Information
  • -20°C
  • Abbreviations
  • Hase
  • Associated Activity
  • pH in deionised water (3mg/ml): 3.5 - 6.5Loss on Drying (LOD): ≤5%Identification: PositiveE.coli: 0Salmonella: 0 Pseudomonas aeruginosa: 0Total Aerobic Microbial Count: 1000Total Combined Yeast & Mould Count: 100
  • Lead Time
  • 18 weeks
  • Storage
  • -20°C
  • Source
  • Ovine Testes
  • Activity
  • ≥400 U/mg
  • EC Number
  • 3.2.1.35
  • Form
  • White to yellowish, amorphous, freeze-dried powder

Technical Documents

Product Information (429.82KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox